JP2021527431A5 - - Google Patents
Info
- Publication number
- JP2021527431A5 JP2021527431A5 JP2020570940A JP2020570940A JP2021527431A5 JP 2021527431 A5 JP2021527431 A5 JP 2021527431A5 JP 2020570940 A JP2020570940 A JP 2020570940A JP 2020570940 A JP2020570940 A JP 2020570940A JP 2021527431 A5 JP2021527431 A5 JP 2021527431A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025075081A JP7891113B2 (ja) | 2018-06-21 | 2025-04-30 | 二重特異性抗ｐｓｍａ×抗ｃｄ２８抗体およびその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688227P | 2018-06-21 | 2018-06-21 | |
| US62/688,227 | 2018-06-21 | ||
| US201862781930P | 2018-12-19 | 2018-12-19 | |
| US201862781980P | 2018-12-19 | 2018-12-19 | |
| US62/781,930 | 2018-12-19 | ||
| US62/781,980 | 2018-12-19 | ||
| US201962815878P | 2019-03-08 | 2019-03-08 | |
| US62/815,878 | 2019-03-08 | ||
| PCT/US2019/038460 WO2019246514A1 (en) | 2018-06-21 | 2019-06-21 | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025075081A Division JP7891113B2 (ja) | 2018-06-21 | 2025-04-30 | 二重特異性抗ｐｓｍａ×抗ｃｄ２８抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527431A JP2021527431A (ja) | 2021-10-14 |
| JP2021527431A5 true JP2021527431A5 (enExample) | 2022-06-23 |
| JP7677796B2 JP7677796B2 (ja) | 2025-05-15 |
Family
ID=67297279
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570940A Active JP7677796B2 (ja) | 2018-06-21 | 2019-06-21 | 二重特異性抗ｐｓｍａ×抗ｃｄ２８抗体およびその使用 |
| JP2025075081A Active JP7891113B2 (ja) | 2018-06-21 | 2025-04-30 | 二重特異性抗ｐｓｍａ×抗ｃｄ２８抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025075081A Active JP7891113B2 (ja) | 2018-06-21 | 2025-04-30 | 二重特異性抗ｐｓｍａ×抗ｃｄ２８抗体およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11548947B2 (enExample) |
| EP (1) | EP3810282A1 (enExample) |
| JP (2) | JP7677796B2 (enExample) |
| KR (2) | KR102875950B1 (enExample) |
| CN (2) | CN119143875A (enExample) |
| AU (2) | AU2019290198B2 (enExample) |
| BR (1) | BR112020025926A2 (enExample) |
| CA (1) | CA3104098A1 (enExample) |
| CL (1) | CL2020003285A1 (enExample) |
| IL (2) | IL325874A (enExample) |
| MA (1) | MA52970A (enExample) |
| MX (1) | MX419677B (enExample) |
| MY (1) | MY205387A (enExample) |
| PH (1) | PH12020552116A1 (enExample) |
| SG (1) | SG11202012729YA (enExample) |
| WO (1) | WO2019246514A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| AU2014336638C1 (en) | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| WO2015073678A1 (en) | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| MX2020010813A (es) | 2018-04-17 | 2021-01-08 | Endocyte Inc | Metodos de tratamiento de cancer. |
| CN119143875A (zh) | 2018-06-21 | 2024-12-17 | 瑞泽恩制药公司 | 双特异性抗psma x抗cd28抗体及其用途 |
| EP3972627A4 (en) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
| CN115380117A (zh) * | 2020-02-18 | 2022-11-22 | 恩多塞特公司 | 治疗表达psma的癌症的方法 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CN116323667A (zh) * | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
| JP7905328B2 (ja) | 2020-09-18 | 2026-08-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用 |
| CN116635425A (zh) * | 2020-11-03 | 2023-08-22 | 德国癌症研究中心公共法律基金会 | 靶细胞限制性、共刺激性、双特异性二价抗cd28抗体 |
| WO2022106629A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| KR20230151513A (ko) | 2021-01-11 | 2023-11-01 | 사나 바이오테크놀로지, 인크. | Cd8 표적 바이러스 벡터의 용도 |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| IL314993A (en) * | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| EP4490192A1 (en) | 2022-03-07 | 2025-01-15 | Novimmune S.A. | Cd28 bispecific antibodies for targeted t cell activation |
| WO2023174925A1 (en) | 2022-03-14 | 2023-09-21 | Novimmune Sa | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2023193239A1 (en) | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
| CN118922449A (zh) * | 2022-04-11 | 2024-11-08 | 江苏恒瑞医药股份有限公司 | 特异性结合psma和cd28的抗原结合分子及其医药用途 |
| EP4558519A1 (en) | 2022-07-22 | 2025-05-28 | Philogen S.p.A. | Anti-cd28 antibodies |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| US20240043560A1 (en) | 2022-08-02 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN117844748A (zh) * | 2022-09-30 | 2024-04-09 | 北京昌平实验室 | 肿瘤抗原特异性记忆性cd8 t细胞的鉴定、体外扩增及应用方法 |
| AU2023362569A1 (en) | 2022-10-21 | 2025-04-24 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
| JP2026508624A (ja) * | 2023-03-13 | 2026-03-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性抗ｃｄ２２×抗ｃｄ２８分子でがんを治療する方法 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025026356A1 (zh) * | 2023-07-31 | 2025-02-06 | 百奥泰生物制药股份有限公司 | 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用 |
| KR20260046131A (ko) | 2023-08-02 | 2026-04-06 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-PSMA x 항-CD28 항체를 이용한 전이성 거세-저항성 전립선암의 치료 방법 |
| WO2025030044A1 (en) | 2023-08-02 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025085610A1 (en) * | 2023-10-18 | 2025-04-24 | Janssen Biotech, Inc. | Combination treatment of prostate cancers with two bispecific antibodies |
| TW202528349A (zh) * | 2023-11-03 | 2025-07-16 | 美商詹努克斯治療有限公司 | 用於靶向psma及cd28之抗體及其用途 |
| TW202545991A (zh) | 2024-01-12 | 2025-12-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｃｄ２８抗體及其用途 |
| WO2025171124A1 (en) * | 2024-02-07 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| TW202544034A (zh) * | 2024-05-06 | 2025-11-16 | 美商榮都醫療公司 | 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體 |
| US20260014252A1 (en) | 2024-07-11 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof |
| WO2026078067A1 (en) | 2024-10-08 | 2026-04-16 | Novimmune Sa | Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof |
| WO2026117523A2 (en) | 2024-11-26 | 2026-06-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a combination of a cancer vaccine and a taaxcd28 bispecific antigen-binding molecule |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| EP1345969B1 (fr) | 2000-12-26 | 2010-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticorps anti-cd28 |
| US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ES2386366T3 (es) * | 2005-02-18 | 2012-08-17 | Medarex, Inc. | Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA) |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| EP3192810A1 (en) * | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
| US20190233534A1 (en) | 2016-07-14 | 2019-08-01 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| KR102531251B1 (ko) | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| KR102520731B1 (ko) | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
| CN112469440B (zh) * | 2018-06-18 | 2024-09-06 | 优瑞科生物技术公司 | 靶向前列腺特异性膜抗原(psma)的构建体和其用途 |
| CN119143875A (zh) | 2018-06-21 | 2024-12-17 | 瑞泽恩制药公司 | 双特异性抗psma x抗cd28抗体及其用途 |
| KR20210104836A (ko) * | 2018-12-19 | 2021-08-25 | 리제너론 파아마슈티컬스, 인크. | 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도 |
| WO2020132024A1 (en) * | 2018-12-19 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
| EP3941941A1 (en) * | 2019-03-22 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
| JP7905328B2 (ja) * | 2020-09-18 | 2026-08-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用 |
-
2019
- 2019-06-21 CN CN202411380163.7A patent/CN119143875A/zh active Pending
- 2019-06-21 JP JP2020570940A patent/JP7677796B2/ja active Active
- 2019-06-21 SG SG11202012729YA patent/SG11202012729YA/en unknown
- 2019-06-21 MX MX2020013804A patent/MX419677B/es unknown
- 2019-06-21 CN CN201980041082.5A patent/CN112351820B/zh active Active
- 2019-06-21 AU AU2019290198A patent/AU2019290198B2/en active Active
- 2019-06-21 BR BR112020025926-8A patent/BR112020025926A2/pt unknown
- 2019-06-21 CA CA3104098A patent/CA3104098A1/en active Pending
- 2019-06-21 MA MA052970A patent/MA52970A/fr unknown
- 2019-06-21 KR KR1020217000650A patent/KR102875950B1/ko active Active
- 2019-06-21 US US16/448,462 patent/US11548947B2/en active Active
- 2019-06-21 IL IL325874A patent/IL325874A/en unknown
- 2019-06-21 IL IL279354A patent/IL279354B2/en unknown
- 2019-06-21 MY MYPI2020006618A patent/MY205387A/en unknown
- 2019-06-21 KR KR1020257034509A patent/KR20250156829A/ko active Pending
- 2019-06-21 WO PCT/US2019/038460 patent/WO2019246514A1/en not_active Ceased
- 2019-06-21 EP EP19740131.8A patent/EP3810282A1/en active Pending
-
2020
- 2020-12-10 PH PH12020552116A patent/PH12020552116A1/en unknown
- 2020-12-17 CL CL2020003285A patent/CL2020003285A1/es unknown
-
2022
- 2022-12-07 US US18/077,139 patent/US20230303696A1/en active Pending
- 2022-12-07 US US18/077,137 patent/US12441800B2/en active Active
-
2025
- 2025-04-30 JP JP2025075081A patent/JP7891113B2/ja active Active
-
2026
- 2026-01-06 AU AU2026200069A patent/AU2026200069A1/en active Pending